Asia Pacific Biopharmaceutical Cmo And Cro Market Size & Outlook

The biopharmaceutical cmo and cro market in Asia Pacific is expected to reach a projected revenue of US$ 16,747.2 million by 2030. A compound annual growth rate of 6.8% is expected of Asia Pacific biopharmaceutical cmo and cro market from 2022 to 2030.

Revenue, 2021 (US$M)
$9,244.4
Forecast, 2030 (US$M)
$16,747.2
CAGR, 2022 - 2030
6.8%
Report Coverage
Asia Pacific

Asia Pacific biopharmaceutical cmo and cro market highlights

  • The Asia Pacific biopharmaceutical cmo and cro market generated a revenue of USD 9,244.4 million in 2021.
  • The market is expected to grow at a CAGR of 6.8% from 2022 to 2030.
  • In terms of segment, mammalian was the largest revenue generating source in 2021.
  • Non-mammalian is the most lucrative source segment registering the fastest growth during the forecast period.
  • Country-wise, India is expected to register the highest CAGR from 2022 to 2030.


Asia Pacific data book summary

Market revenue in 2021USD 9,244.4 million
Market revenue in 2030USD 16,747.2 million
Growth rate6.8% (CAGR from 2021 to 2030)
Largest segmentMammalian
Fastest growing segmentNon-mammalian
Historical data covered2017 - 2020
Base year for estimation2021
Forecast period covered2022 - 2030
Quantitative unitsRevenue in USD million
Market segmentationMammalian, Non-mammalian
Key market players worldwideBoehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung BioLogics, Thermo Fisher Scientific Inc, R1 RCM Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Binex, Charles River Laboratories International Inc, Icon PLC, PAREXEL, Labcorp Holdings Inc


Other key industry trends

  • In terms of revenue, Asia Pacific region accounted for 31.4% of the global biopharmaceutical cmo and cro market in 2021.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Latin America is the fastest growing regional market and is projected to reach USD 1,536.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biopharmaceutical CMO And CRO Market Companies

Name Profile # Employees HQ Website

Asia Pacific biopharmaceutical cmo and cro market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.


Mammalian was the largest segment with a revenue share of 55.82% in 2021. Horizon Databook has segmented the Asia Pacific biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.


The Asia Pacific biopharmaceuticals CMO & CRO market is growing at a significant rate and the region is expected to emerge as the fastest-growing market for biopharmaceutical R&D and manufacturing. This growth can be attributed to various factors, such as regulatory changes, improving infrastructure, and presence of a large number of potential study subjects.


Several biopharma companies from the U.S. are considering development of pharma products in Asian countries owing to growing cost of R&D in their home country. Low-cost production facilities and cheap labor are available in Asian countries. The cost of production in Asian countries is 30% to 60% lesser than that in Western countries.


Asia Pacific region has been exhibiting continuous growth in biomanufacturing, and this is anticipated to considerably boost biomanufacturing in China and India. Moreover, conducting clinical trials in Asian countries, such as India, is relatively less expensive as compared to western countries, and this has also resulted in migration of several companies to this region.

Reasons to subscribe to Asia Pacific biopharmaceutical cmo and cro market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Asia Pacific biopharmaceutical cmo and cro market databook

  • Our clientele includes a mix of biopharmaceutical cmo and cro market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific biopharmaceutical cmo and cro market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Asia Pacific biopharmaceutical cmo and cro market size, by country, 2017-2030 (US$M)

Asia Pacific Biopharmaceutical CMO And CRO Market Outlook Share, 2021 & 2030 (US$M)

Asia Pacific biopharmaceutical cmo and cro market size, by country, 2017-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more